Evogene

Company Profile

Evogene had its IPO on 2008-03-05 under the ticker symbol EVGN.

The company operates in the Healthcare sector and Biotechnology industry. Evogene has a staff strength of 137 employees.

Stock update

Shares of Evogene opened at $0.73 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.72 - $0.73, and closed at $0.72.

This is a -1.33% slip from the previous day's closing price.

A total volume of 26,832 shares were traded at the close of the day’s session.

In the last one week, shares of Evogene have slipped by -3.96%.

Evogene's Key Ratios

Evogene has a market cap of $24.57 million, indicating a price to book ratio of 0.9638 and a price to sales ratio of 21.988.

In the last 12-months Evogene’s revenue was $1.68 million with a gross profit of $766000 and an EBITDA of $-25087000. The EBITDA ratio measures Evogene's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Evogene’s operating margin was -1608.42% while its return on assets stood at -25.43% with a return of equity of -60.78%.

In Q1, Evogene’s quarterly earnings growth was a positive 0% while revenue growth was a positive 112.2%.

Evogene’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.56 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Evogene’s profitability.

Evogene stock is trading at a EV to sales ratio of 1.9294 and a EV to EBITDA ratio of -0.0887. Its price to sales ratio in the trailing 12-months stood at 21.988.

Evogene stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$49.48 million

Total Liabilities

$5.36 million

Operating Cash Flow

$0

Capital Expenditure

$359000

Dividend Payout Ratio

0%

Evogene ended 2024 with $49.48 million in total assets and $0 in total liabilities. Its intangible assets were valued at $49.48 million while shareholder equity stood at $22.09 million.

Evogene ended 2024 with $0 in deferred long-term liabilities, $5.36 million in other current liabilities, in common stock, $-239978000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $23.00 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $10.31 million.

Evogene’s total current assets stands at $31.41 million while long-term investments were $0 and short-term investments were $5.80 million. Its net receivables were $250000.00 compared to accounts payable of $1.15 million and inventory worth $591000.00.

In 2024, Evogene's operating cash flow was $0 while its capital expenditure stood at $359000.

Comparatively, Evogene paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.72

52-Week High

$1.3

52-Week Low

$0.55

Analyst Target Price

$1.5

Evogene stock is currently trading at $0.72 per share. It touched a 52-week high of $1.3 and a 52-week low of $1.3. Analysts tracking the stock have a 12-month average target price of $1.5.

Its 50-day moving average was $0.94 and 200-day moving average was $0.76 The short ratio stood at 5.19 indicating a short percent outstanding of 0%.

Around 203.8% of the company’s stock are held by insiders while 338.8% are held by institutions.